Trial Profile

A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapolsertib (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; First in man
Acronyms DIAMOND; DIAMOND-01
Sponsors Menarini; Menarini Ricerche

Most Recent Events

29 Apr 2025 Protocol has been amended to include new treatment arms (experimental arms changed from 1 to 6).
23 May 2023 Status changed from active, no longer recruiting to completed.
24 Mar 2023 According to Ryvu media release, updates from this study are expected in 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com